Workflow
舒泰神(300204.SZ)发布前三季度业绩,归母净亏损3068.95万元
Staidson BioPharmStaidson BioPharm(SZ:300204) 智通财经网·2025-10-28 11:08

Core Viewpoint - The company reported a significant decline in revenue and incurred net losses in the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 181 million yuan, representing a year-on-year decrease of 30.82% [1] - The net loss attributable to shareholders of the listed company was 30.6895 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 34.3569 million yuan [1] - The basic loss per share was 0.06 yuan [1]